A longtime member of Perrigo Co. PLC’s executive leadership team has resigned.
Judy L. Brown, who has been chief financial officer of the store-brand pharmaceuticals maker for nearly 11 years, has resigned to take another position.
While Perrigo stated that Brown “will take a position with another company in the pharmaceutical industry, beginning on April 1, 2017,” it did not name the company.
The Wall Street Journal reported online Monday that she will join California-based pharmaceutical industry giant Amgen Inc. Brown will join Amgen to run its global business services unit and its global internal audit function, the Journal reported.
It stated that she told Perrigo’s management of her decision last week.
Accounting and finance veteran Ron Winowiecki, who has been with Perrigo for about eight years, has been named acting CFO by Perrigo CEO John T. Hendrickson.
In a press release, Hendrickson praised Brown’s work, saying, “Judy’s leadership has been instrumental in developing a high caliber finance team at Perrigo and assisted our efforts to drive growth across our global platform. On behalf of the Board of Directors and management, I would like to thank Judy for her contributions to Perrigo over her more than 15-year tenure with the Company, and wish her all the best in her future endeavors.”
Brown was named executive vice president and CFO in July 2006. Oversight of business operations was added to her responsibilities in May of 2016. She was vice president and corporate controller of the company from September of 2004 to July of 2006. Prior to that, she held various senior positions in finance and operations at Whirlpool Corp.
Perrigo said in its press release that it will conduct a thorough search to identify a new permanent chief financial officer, but Winowiecki would be a “key candidate” for the position.
Winowiecki has been Perrigo’s senior vice president in business finance since January 2014. Before that, he was vice president in treasury and accounting shared services from September of 2011 to December of 2013 and was corporate vice president and treasurer from October 2008 to August 2011.
Winowiecki has a bachelor’s degree in accounting from Hope College and a master’s degree in business administration from Western Michigan University.
Speaking of Winowiecki, Hendrickson said, “Ron has almost 30 years of accounting and finance experience, devoting nearly 15 years to leading global public company finance organizations in the capacities of corporate controller, treasurer and chief accounting officer, including eight years at Perrigo, most recently as senior vice president, business finance. I am confident that this will be a seamless transition and that Ron will provide Perrigo and our financial team with strong leadership. I look forward to continuing to work alongside Ron.”
Perrigo also announced Monday that Svend Andersen has been appointed executive vice president and president of Consumer Healthcare International. The CHCI segment comprises Perrigo’s branded consumer healthcare business as well as its legacy international businesses. He will report directly to Hendrickson and join Perrigo’s executive committee.
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.